Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan

Bibliography

• Reisberg B, Doody R, Stöffler A, et al. for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41
   Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, et al. for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24
   PubMed Web of Science ®Google Scholar
• Winblad B, Jones RW, Wirth Y, et al. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24:20-7
   PubMed Web of Science ®Google Scholar
• Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723
   PubMed Web of Science ®Google Scholar
• Kitamura S, Homma A, Nakamura Y, et al. Phase II study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease –Efficacy, safety and recommended dose. Jpn J Geriatr Psychiat 2011;22:453-63
   Google Scholar
• Niina R, Homma A, Sugai Y, et al. Reliability, validity and clinical availability of a Japanese version of severe impairment battery (SIB) and a Japanese version of modified Alzheimer's disease cooperative study-activities of daily living inventory (ADCS-ADL). Jpn J Geriatr Psychiat 2005;16:683-91
   Google Scholar
• Homma A, Asada T, Arai H, et al. Clinical global assessment for dementia patients. Clinician's interview-based impression of change plus-Japan (CIBIC plus-J) concept and assessment manual. Jpn J Geriatr Psychiat 1997;8:855-69
   Google Scholar
• Nakamura Y, Homma A, Kitamura S, et al. Phase III study of memantine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease –Efficacy and safety. Jpn J Geriatr Psychiat 2011;22:464-73
   Google Scholar
• Ferris S, Ihl R, Robert P, et al. Treatment effects of memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement 2009;5:369-74
   PubMed Web of Science ®Google Scholar
• Ferris S, Ihl R, Robert P, et al. Severe impairment battery language scale: a Language Assessment tool for Alzheimer's disease patients. Alzheimers Dement 2009;5:375-9
   PubMed Web of Science ®Google Scholar
• Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005;20:459-64
   PubMed Web of Science ®Google Scholar
• Asada T, Homma A, Kimura M, et al. Study on the reliability of the Japanese version of the BEHAVE-AD. Jpn J Geriatr Psychiat 1999;10:825-34
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association, Washington, DC; 1994
   Google Scholar
• McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease; report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189-98
   PubMed Web of Science ®Google Scholar
• Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653-9
   PubMed Web of Science ®Google Scholar
• Homma A, Asada T, Arai H, et al. Clinical assessment for patients with age-associated dementia. Global and psychometric assessment. Jpn J Geriatr Psychiat 1999;10:193-229
   Google Scholar
• Panisset M, Roudier M, Saxton J, et al. Severe impairment battery; a neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-5
   PubMed Web of Science ®Google Scholar
• Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment, battery; concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S51-6
   PubMedGoogle Scholar
• Homma A, Niina R, Ishii T, et al. Development of a new rating scale for dementia in the elderly: mental function impairment scale (MENFIS). Jpn J Geriatr Psychiat 1991;10:1217-22
   Google Scholar
• Statistical principles for clinical trials (The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH] E9). ICH, Geneva, Switzerland. Available from: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/statistical-principles-for-clinical-trials.html [Last accessed 10 December 2013]
   Google Scholar
• Schmitt F, van Dyck C, Wichems C, et al. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord 2006;20:255-62
   PubMed Web of Science ®Google Scholar
• Tocco M, Bayles K, Lopez OL, et al. Effects of memantine treatment on language abilities and functional communication: a review of data. Aphasiology 2014;28:236-57
   Web of Science ®Google Scholar
• Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341-8
   PubMed Web of Science ®Google Scholar
• Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23:537-45
   PubMed Web of Science ®Google Scholar
• Survey of Institutions and Establishments for Long-term Care 2010: summary of Results. Ministry of Health, Labour and Welfare, Tokyo, Japan. Available from: http://www.mhlw.go.jp/english/index.html [Last accessed 10 December 2013]
   Google Scholar
• Nakamura Y. Investigation of the effects of use of nursing care services on changes of status of nursing care for patients with dementia and consideration of the effect on CIBIC-plus by these changes. Jpn J Geriatr Psychiat 2010;21:685-94
   Google Scholar
• Nakamura Y, Kitamura S, Homma A, et al. Tolerability and efficacy of the long-term administration of memantine hydrochloride (Memary®) in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat 2014; In press
   Google Scholar
• Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-8
   PubMed Web of Science ®Google Scholar